Intelligo

Private limited company · Ålesund

PHARMA NORDIC AS

ActiveWholesale of pharmaceutical and medical goods (46.460)

Founded
24 Feb 2022
Employees
6
Chief executive
Bent Lorang Andreassen
Business address
5 etg, Storgata 38, 6002 Ålesund

The life line 2022–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 12.2m.

  1. Kapital§ 14
  2. Fullmakt kapitalforhøyelse§ 14
  3. Managing director took office§ 07
  4. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

PHARMA NORDIC AS is a private limited company in Ålesund, founded in 2022, in the industry wholesale of pharmaceutical and medical goods. The chief executive is Bent Lorang Andreassen, and the chair of the board is Helge Ivar Strømskag. In 2025 the company had NOK 12.2m in operating revenue and a net profit of NOK −9.9m. The largest owner is HAVO INVEST AS with 16.9%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 27 Oct 2026

  • New address AVERØY
  • New address 6530
  • New address Bruhagen Sentrumsbygg, Averøyveien 34
  • Fullmakt konvertibelt lån

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

2 points

  • NoteOperating loss three years running, 2023–2025
  • OKEquity ratio 77.4%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue NOK 12.2m in 2025

Revenue

NOK 12.2m

+196.4% from 2024

20232025

Operating profit

NOK −12.3m

+30.4% from 2024

20232025

Net profit

NOK −9.9m

+30.0% from 2024

20232025

Equity

NOK 41.4m

+107.1% from 2024

20232025

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Wages and social costs 55%
  • Depreciation 0%
  • Other operating costs 119%
  • Not specified in the source 27%

Costs exceeded revenue: the operating result was NOK −12.3m.

Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 77.4%

RevenueNOK 12.2m Operating margin−101.0% Equity ratio77.4% Revenue growth+196.4%
  • PHARMA NORDIC AS, 2025
  • Industry median, assumed: NOK 8.5m · 4.3% · 41.6% · +7.3%

Equity NOK 41.4m77% of the assets (NOK 53.5m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 538 companies in 46.460 Wholesale of pharmaceutical and medical goods, not stated by the source.

Finances

§ 06 Accounts

4 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue12,1934,113158
Operating profit−12,311−17,686−7,556
Profit before tax−12,606−18,049−7,625
Net profit−9,883−14,112−5,986
Total assets53,53123,7704,905
Equity41,41019,998710
Liabilities12,1223,7734,196

Source: the Register of Company Accounts, read 15 Nov 2026 · All 4 years →

Management and ownership

§ 07 Officers

7 officers now

The board: 5 members

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 7 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

Daglig leder og styrets leder i fellesskap.

May sign for the company:

Daglig leder og styrets leder i fellesskap.

Power of procuration:

Daglig leder eller styrets leder hver for seg.

The board has 3 authorisations in force now: capital increase, until 8 Jun 2028; fullmakt konvertibelt lån, until 8 Jun 2028; capital increase, until 26 May 2027.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 5 Oct 2026

Management and ownership

§ 09 Owners

50 shareholders · largest 16.9%

OwnerShare
HAVO INVEST AS
16.9%
BA&SA HOLDING AS
10.2%
SIMPLYFISH AS
9.7%
47 others63.2%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 50 owners →

Management and ownership

§ 10 Group

1 subsidiary

PHARMA NORDIC AS parent company

Share held. Source: the Tax Administration's shareholder register, fetched 30 Jul 2026 · The whole group →

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

73 connections

  • Person
  • Company

6 people link PHARMA NORDIC AS to 61 other companies: Helge Ivar Strømskag 31, Siv Jensen 13, Geir Riise 9, Bent Lorang Andreassen 3, Heidi Kristin Bjørnslett Haugen 4 and Hans Tomter 1.

Source: the Brønnøysund Register Centre, read 23 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

44 since 2022

Events per year

20222026

  • Notices36
  • Register changes6
  • Owners in and out2

Since 2022: 36 announcements, 6 register changes and 2 new and 0 former owners. Most happened in 2025 and 2026.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 2 Nov 2026. Register changes are Intelligo's own observations. · All 44 events →

Events and registers

§ 14 Notices

36, latest 26 Oct 2026

  • Fullmakt konvertibelt lån
  • Fullmakt kapitalforhøyelse
  • Godkjente årsregnskap

Source: The Brønnøysund Register Centre's announcements ↗, read 2 Nov 2026 · All 36 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 12 Apr 2022
  • VATRegistered
  • The Register of Business EnterprisesRegistered 12 Apr 2022
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Lisensiering - salg, markedsføring, forskning og utvikling av naturbaserte legemidler, medisinsk teknisk utstyr, legemidler og annet helserelaterte produkter, samt det som naturlig står i forbindelse med dette.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 46.460

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

7 questions

  • Who is the chief executive of PHARMA NORDIC AS?
    Bent Lorang Andreassen, since 2022. § 07
  • Who owns PHARMA NORDIC AS?
    50 shareholders. The largest is HAVO INVEST AS with 16.9%, BA&SA HOLDING AS with 10.2% and SIMPLYFISH AS with 9.7%. § 09
  • What was the revenue in 2025?
    NOK 12.2m in the company. § 06
  • Who can sign for PHARMA NORDIC AS?
    Daglig leder og styrets leder i fellesskap. § 08
  • Who is the auditor?
    VEKST REVISJON AS, from 10 Sep 2025. § 07
  • Where is PHARMA NORDIC AS based?
    5 etg, Storgata 38, 6002 Ålesund.
  • When was PHARMA NORDIC AS founded?
    24 Feb 2022, registered in the Register of Business Enterprises 12 Apr 2022. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose